Welcome to our dedicated page for Merrimack Pharma news (Ticker: MACK), a resource for investors and traders seeking the latest updates and insights on Merrimack Pharma stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Merrimack Pharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Merrimack Pharma's position in the market.
Merrimack Pharmaceuticals (Nasdaq: MACK) has extended its Section 382 net operating loss rights plan until December 2, 2025, to preserve its valuable net operating loss carryforwards and tax attributes. This plan aims to mitigate corporate tax payments associated with potential milestone payments. CEO Gary Crocker emphasized that using these NOLs could enhance future shareholder distributions. However, the extension requires shareholder approval at the upcoming 2023 annual meeting.
Merrimack Pharmaceuticals (MACK) announced that Ipsen reported positive results from the Phase III NAPOLI 3 trial of Onivyde, showing a significant improvement in overall survival for metastatic pancreatic ductal adenocarcinoma patients. Ipsen plans to file a supplemental New Drug Application with the FDA, potentially triggering milestone payments for Merrimack.
CEO Gary Crocker expressed optimism about the results, highlighting potential future payments up to $450 million depending on regulatory approval.
Merrimack Pharmaceuticals (MACK) reported a net loss of
Merrimack Pharmaceuticals reported a net loss of $478,000 for Q2 2022, or $0.04 per share, an improvement from a loss of $759,000 or $0.06 per share in Q2 2021. Operating expenses decreased significantly to $486,000 from $778,000 year-over-year. As of June 30, 2022, the company had $13.4 million in cash and equivalents, down from $14.2 million at the end of 2021. Merrimack continues to rely on milestone payments from Ipsen and Elevation Oncology, with potential payments totaling $450 million and $54.5 million respectively.
Merrimack Pharmaceuticals (NASDAQ: MACK) reported that Ipsen's Phase 3 trial of Onivyde for small cell lung cancer did not meet its primary endpoint of overall survival. However, Onivyde showed a significant improvement in the secondary objective response rate. The safety profile remained unchanged, and no new safety concerns were identified. Ipsen will conduct further analysis before determining the next steps. Merrimack is entitled to potential milestone payments from Ipsen linked to Onivyde's future approvals.
Merrimack Pharmaceuticals (MACK) reported its first quarter 2022 results with a net loss of
Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) reported a net loss of
Merrimack Pharmaceuticals reported a net loss of $0.5 million for Q3 2021, an improvement from $1.0 million the previous year. Their cash position increased to $14.6 million from $14.0 million at year-end 2020, aided by operational cost reductions and receipt of a tax refund. Updates from partners Ipsen and Elevation Oncology indicate ongoing progress in clinical trials, including data expected from key trials in 2022 and 2023 that could trigger milestone payments up to $450 million.
Merrimack Pharmaceuticals (Nasdaq:MACK) reported a net loss of $0.8 million for Q2 2021, improved from a $1.2 million loss in Q2 2020. General and administrative expenses have decreased to $0.8 million from $1.2 million year-over-year. As of June 30, 2021, cash and equivalents rose to $14.9 million, up from $14.0 million at the end of 2020, primarily due to a federal tax refund. Progress continues on clinical programs with Ipsen Pharmaceuticals and Elevation Oncology that could lead to future milestone payments.
Merrimack Pharmaceuticals (MACK) reported a net loss of $3.0 million for the fiscal year 2020, significantly improved from a net loss of $17.3 million in 2019. The company saw a reduction in general and administrative expenses, totaling $5.0 million for the year, down from $16.2 million the previous year. As of December 31, 2020, Merrimack held $14.0 million in cash and equivalents, down from $16.6 million in 2019. The company remains focused on potential milestone payments from Ipsen Pharmaceuticals and Elevation Oncology, with ongoing clinical developments that could yield future income.